Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

MALVERN, Pa., April 26, 2024 -- Ocugen, Inc. , a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the...

Related Keywords

,Shankar Musunuri ,Murthy Chavali ,Benjamin Bakall ,Borooah Shyamanga ,Arunk Upadhyay ,Paul Yang ,Nalin Mehta ,Sahar Matloob ,Tarun Upadhyay ,Nieraj Jain ,Joses Pulido ,University Of Miami ,Ocugen Inc ,Head Of Research Development ,Seattle Convention Center ,Nuclear Hormone Receptor ,Head Of Communications ,Exchange Commission ,Association For Research ,Linkedin ,Clinical Development ,Hormone Receptor Based Gene Modifier Therapy ,Retinitis Pigmentosa Associated ,Byron Lam ,Endowed Chair ,March Building ,Gene Agnostic Modifier Therapy ,Retinitis Pigmentosa ,Study Results ,Melight Study Design ,Chief Scientific Officer ,Show Floor ,Educational Lounge ,Multifactorial Therapeutic Intervention ,Dry Age Related Macular Degeneration ,Huma Qamar ,Chief Medical Officer ,Novel Modifier Approach ,Orphan Receptor ,Private Securities Litigation Reform Act ,Markets ,